Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Current ratio | ||||||
| Quick ratio | ||||||
| Cash ratio |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The liquidity position of the company demonstrates a generally declining trend from 2021 through 2023, followed by a partial recovery in 2024 and 2025. All three liquidity ratios – current, quick, and cash – exhibit this pattern, though to varying degrees. The observed changes suggest a potential shift in the company’s short-term asset management and financing strategies.
- Current Ratio
- The current ratio decreased from 1.40 in 2021 to a low of 0.91 in 2023, indicating a diminishing ability to cover short-term liabilities with short-term assets. A subsequent increase to 1.17 in 2024 and a slight decrease to 1.16 in 2025 suggest some stabilization, but the ratio remains below the 2021 level. This indicates a reduced cushion for meeting immediate obligations compared to the beginning of the period.
- Quick Ratio
- The quick ratio, which excludes inventory from current assets, shows a more pronounced decline than the current ratio. It fell from 1.00 in 2021 to 0.50 in 2023, signifying a weakening ability to meet short-term obligations with the most liquid assets. The ratio improved to 0.74 in 2024 and then to 0.69 in 2025, but remains considerably lower than the 2021 value. This suggests a growing reliance on inventory to meet short-term liabilities.
- Cash Ratio
- The cash ratio experienced the most significant decrease, dropping from 0.73 in 2021 to 0.27 in 2023. This indicates a substantial reduction in the proportion of current assets held as cash. A partial recovery to 0.48 in 2024 and 0.37 in 2025 offers some improvement, but the ratio remains significantly below the initial level. This suggests a strategic decision to deploy cash into other assets or to reduce cash holdings, potentially increasing financial risk in the short term.
Overall, the trends across these ratios suggest a decreasing liquidity buffer between 2021 and 2023, followed by a modest recovery in the subsequent two years. While the ratios show some improvement after 2023, they have not returned to their initial levels, indicating a sustained change in the company’s liquidity profile.
Current Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Current ratio1 | ||||||
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Current Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Current Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited fluctuating behavior over the five-year period. Initial values demonstrated a generally healthy liquidity position, which subsequently experienced a decline before stabilizing. A detailed examination of the trend reveals key observations regarding the company’s short-term financial health.
- Overall Trend
- The current ratio began at 1.40 in 2021, indicating the company possessed $1.40 of current assets for every $1.00 of current liabilities. This ratio decreased to 1.22 in 2022, suggesting a slight weakening in liquidity. A more pronounced decline occurred in 2023, with the ratio falling to 0.91, signifying that current liabilities exceeded current assets. The ratio then recovered to 1.17 in 2024 and remained relatively stable at 1.16 in 2025.
- Year-over-Year Changes
- From 2021 to 2022, the current ratio decreased by 0.18, reflecting a modest reduction in the company’s ability to cover short-term obligations with current assets. The largest year-over-year decrease was observed between 2022 and 2023, with a drop of 0.31, indicating a substantial deterioration in short-term liquidity. The subsequent increase of 0.26 from 2023 to 2024 suggests corrective actions or favorable changes in the composition of current assets and liabilities. The minimal change between 2024 and 2025 indicates a stabilization of the short-term financial position.
- Underlying Component Analysis
- The decrease in the current ratio in 2023 was driven by a larger increase in current liabilities ($47,794 million) compared to the decrease in current assets ($43,333 million). The recovery in 2024 and stabilization in 2025 were supported by an increase in current assets ($50,358 million in 2024 and $42,898 million in 2025) coupled with a decrease in current liabilities ($42,995 million in 2024 and $36,984 million in 2025). These movements suggest active management of working capital.
In conclusion, while the current ratio experienced a period of decline, it demonstrated a recovery and subsequent stabilization. The fluctuations highlight the importance of monitoring both current asset and current liability levels to maintain a healthy short-term financial position.
Quick Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | ||||||
| Short-term investments | ||||||
| Trade accounts receivable, net of allowance for doubtful accounts | ||||||
| Total quick assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Quick ratio1 | ||||||
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Quick Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Quick Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio demonstrates a declining trend from 2021 to 2023, followed by a partial recovery in the subsequent two years. This indicates a shifting pattern in the company’s ability to meet its short-term obligations with its most liquid assets.
- Quick Ratio Trend
- In 2021, the quick ratio stood at 1.00, suggesting the company held $1.00 of quick assets for every $1.00 of current liabilities. A subsequent decrease was observed in 2022, with the ratio falling to 0.80. This decline continued into 2023, reaching a low of 0.50, indicating a reduced capacity to cover immediate liabilities with highly liquid assets.
- A moderate recovery occurred in 2024, with the quick ratio increasing to 0.74. This upward movement persisted into 2025, reaching 0.69, though the ratio remained below the 2021 level.
- Asset and Liability Dynamics
- Total quick assets decreased from $42,548 million in 2021 to $33,684 million in 2022, and further to $23,867 million in 2023. The subsequent years saw increases to $31,940 million in 2024 and $25,470 million in 2025, but these levels did not return to the initial 2021 value.
- Current liabilities remained relatively stable between 2021 and 2023, fluctuating around $42 billion. An increase to $47,794 million was noted in 2023, contributing to the lower quick ratio. A decrease to $42,995 million in 2024 and $36,984 million in 2025 partially offset this effect.
The combined effect of decreasing quick assets and fluctuating current liabilities resulted in the observed trend in the quick ratio. While the ratio showed some improvement in the latter two years, the company’s ability to cover short-term liabilities with its most liquid assets remains lower than in 2021.
Cash Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | ||||||
| Short-term investments | ||||||
| Total cash assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Cash ratio1 | ||||||
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Cash Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Cash Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibited a declining trend from 2021 to 2023, followed by a partial recovery in 2024 and a subsequent decrease in 2025. This indicates a shifting pattern in the company’s ability to meet its short-term obligations with only its most liquid assets.
- Cash Ratio Trend
- In 2021, the cash ratio stood at 0.73, suggesting the company held 73 cents of cash for every dollar of current liabilities. This ratio decreased to 0.54 in 2022, representing a moderate reduction in immediate liquidity. A more substantial decline occurred in 2023, with the cash ratio falling to 0.27, indicating a significantly diminished capacity to cover current liabilities with available cash. The ratio experienced a partial rebound in 2024, rising to 0.48, but then decreased again to 0.37 in 2025.
Total cash assets generally decreased over the period, although a notable increase was observed between 2023 and 2024. This increase in cash assets did not fully translate into an equivalent improvement in the cash ratio, suggesting concurrent changes in current liabilities.
- Cash Assets
- Total cash assets decreased from US$31,069 million in 2021 to US$22,732 million in 2022, and further to US$12,690 million in 2023. A significant increase was then recorded in 2024, reaching US$20,477 million, before decreasing to US$13,596 million in 2025. This volatility in cash holdings likely influenced the fluctuations in the cash ratio.
Current liabilities remained relatively stable between 2021 and 2023, with a slight decrease in 2022. A rise was observed in 2023, followed by a decrease in 2024 and a further decrease in 2025. The interplay between cash assets and current liabilities is a key driver of the observed cash ratio trends.
- Current Liabilities
- Current liabilities were US$42,671 million in 2021, decreasing slightly to US$42,138 million in 2022. An increase to US$47,794 million was recorded in 2023, followed by a decrease to US$42,995 million in 2024, and a further decrease to US$36,984 million in 2025. These fluctuations, in conjunction with the changes in cash assets, impacted the company’s cash ratio.
The decreasing trend in the cash ratio from 2021 to 2023, and the subsequent fluctuations, warrant further investigation into the underlying reasons for these changes, including potential shifts in working capital management or financing strategies.